ABUS
Price
$3.24
Change
+$0.05 (+1.57%)
Updated
Jul 3 closing price
Capitalization
620.55M
26 days until earnings call
AGEN
Price
$6.07
Change
+$0.56 (+10.16%)
Updated
Jul 3 closing price
Capitalization
166.42M
Interact to see
Advertisement

ABUS vs AGEN

Header iconABUS vs AGEN Comparison
Open Charts ABUS vs AGENBanner chart's image
Arbutus Biopharma
Price$3.24
Change+$0.05 (+1.57%)
Volume$354.26K
Capitalization620.55M
Agenus
Price$6.07
Change+$0.56 (+10.16%)
Volume$1.27M
Capitalization166.42M
ABUS vs AGEN Comparison Chart in %
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. AGEN commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and AGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (ABUS: $3.24 vs. AGEN: $6.07)
Brand notoriety: ABUS and AGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 43% vs. AGEN: 108%
Market capitalization -- ABUS: $620.55M vs. AGEN: $166.42M
ABUS [@Biotechnology] is valued at $620.55M. AGEN’s [@Biotechnology] market capitalization is $166.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileAGEN’s FA Score has 0 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • AGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, AGEN is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 5 TA indicator(s) are bullish while AGEN’s TA Score has 5 bullish TA indicator(s).

  • ABUS’s TA Score: 5 bullish, 5 bearish.
  • AGEN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AGEN is a better buy in the short-term than ABUS.

Price Growth

ABUS (@Biotechnology) experienced а +1.25% price change this week, while AGEN (@Biotechnology) price change was +23.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

ABUS is expected to report earnings on Jul 31, 2025.

AGEN is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABUS($621M) has a higher market cap than AGEN($166M). AGEN YTD gains are higher at: 121.533 vs. ABUS (-0.917). ABUS has higher annual earnings (EBITDA): -75.1M vs. AGEN (-81.06M). ABUS has more cash in the bank: 113M vs. AGEN (18.5M). ABUS has less debt than AGEN: ABUS (1.19M) vs AGEN (92M). AGEN has higher revenues than ABUS: AGEN (99.5M) vs ABUS (6.4M).
ABUSAGENABUS / AGEN
Capitalization621M166M374%
EBITDA-75.1M-81.06M93%
Gain YTD-0.917121.533-1%
P/E RatioN/A0.20-
Revenue6.4M99.5M6%
Total Cash113M18.5M611%
Total Debt1.19M92M1%
FUNDAMENTALS RATINGS
ABUS vs AGEN: Fundamental Ratings
ABUS
AGEN
OUTLOOK RATING
1..100
5284
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
76100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6135
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABUS's Valuation (65) in the Biotechnology industry is in the same range as AGEN (97). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

ABUS's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as AGEN (100). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

ABUS's SMR Rating (98) in the Biotechnology industry is in the same range as AGEN (100). This means that ABUS’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's Price Growth Rating (35) in the Biotechnology industry is in the same range as ABUS (61). This means that AGEN’s stock grew similarly to ABUS’s over the last 12 months.

AGEN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ABUS (100). This means that AGEN’s stock grew similarly to ABUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSAGEN
RSI
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
MACD
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
77%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
78%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BKEAF1.440.03
+2.13%
Bank of East Asia Limited
DPNEF0.02N/A
N/A
Daphne International Holdings Ltd.
FCRM0.05N/A
N/A
Franklin Credit Management Corp.
TNRSF18.36N/A
N/A
Tenaris S.A.
OBSJF0.35N/A
N/A
Obrascon Huarte Lain Brasil S.A.

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+1.57%
IDYA - ABUS
47%
Loosely correlated
+0.82%
IMVT - ABUS
44%
Loosely correlated
+0.83%
ARRY - ABUS
43%
Loosely correlated
+11.93%
DNLI - ABUS
43%
Loosely correlated
-1.41%
AXON - ABUS
42%
Loosely correlated
+2.70%
More